Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Chiou, S.Y.; Lai, G.W.; Lin, L.Y.; Lin, G.
    Kinetics and mechanisms of cholesterol esterase inhibition by cardiovascular drugs in vitro (2006), Indian J. Biochem. Biophys., 43, 52-55.
    View publication on PubMed

Application

EC Number Application Comment Organism
3.1.1.13 medicine lowering of cholesterol levels in plasma low-density lipoprotein by cardiovascular drugs such as lovastatin, simvastatin, amlodipine, besylate, nifedipine, and hydralazine hydrochloride may result from inhibition of cholesterol esterase Bos taurus

Inhibitors

EC Number Inhibitors Comment Organism Structure
3.1.1.13 amlodipine mixed-type, study on kinetics in presence of Triton X-100 or taurocholate Bos taurus
3.1.1.13 besylate mixed-type, study on kinetics in presence of Triton X-100 or taurocholate Bos taurus
3.1.1.13 hydralazine hydrochloride mixed-type, study on kinetics in presence of Triton X-100 or taurocholate Bos taurus
3.1.1.13 lovastatin mixed-type, study on kinetics in presence of Triton X-100 or taurocholate Bos taurus
3.1.1.13 additional information pKi values of cardiovascular drug inhibitors such as lovastatin, simvastatin, amlodipine, besylate, nifedipine, and hydralazine hydrochloride correlate with their molecular weight Bos taurus
3.1.1.13 nifedipine mixed-type, study on kinetics in presence of Triton X-100 or taurocholate Bos taurus
3.1.1.13 simvastatin mixed-type, study on kinetics in presence of Triton X-100 or taurocholate Bos taurus

Organism

EC Number Organism UniProt Comment Textmining
3.1.1.13 Bos taurus
-
-
-